Hemafer-S (Iron)

Hemafer‑S is indicated for the treatment of iron deficiency anemia in patients who require rapid repletion of iron stores.

• Adults with documented iron deficiency anemia who cannot tolerate oral iron.
• Patients undergoing surgery with anticipated blood loss.
• Individuals with chronic kidney disease receiving dialysis.
• Pregnant women with confirmed iron deficiency when oral therapy is ineffective.
• Patients with inflammatory bowel disease associated anemia.

The safety profile of Hemafer‑S includes both frequently observed and less common adverse reactions that may occur after intravenous administration.

Common

• Transient headache or dizziness.
• Nausea or mild vomiting.
• Injection site discomfort or erythema.
• Temporary metallic taste in the mouth.

Serious

• Severe hypersensitivity reactions including anaphylaxis.
• Acute hypotension or cardiovascular collapse.
• Iron overload leading to organ dysfunction.

Clinicians should consider several precautionary measures before prescribing Hemafer‑S to ensure patient safety and optimal therapeutic outcome.

• Assess baseline hemoglobin, ferritin, and transferrin saturation levels.
• Avoid use in patients with known hypersensitivity to iron preparations.
• Monitor vital signs during and after infusion for signs of hypotension.
• Adjust dose in patients with hepatic or renal impairment.
• Use caution in individuals with active infections or inflammatory conditions.
• Ensure appropriate iron repletion targets to prevent overload.

Intravenous iron can interact with certain medications and substances, requiring attention to avoid reduced efficacy or increased risk.

Avoid

• Concurrent administration of high‑dose vitamin C or ascorbic acid, which may increase free iron.
• Use with other parenteral iron products due to cumulative iron load.

Use with caution

• Antimicrobial agents such as tetracyclines, which may chelate iron and reduce absorption.
• Loop diuretics, as rapid iron infusion can affect fluid balance.
• Anticoagulants, because infusion‑related hypotension may enhance bleeding risk.